業 績 一 覧 2025

原著

1. Takahashi M, Nakamura K, Chiyoda T, Okada C, Nohara S, Takamatsu R, Yanazume S, Kobayashi H, Nishihara H, Nishihara H. Transcriptome concordance between borderline tumors and endometrioid carcinoma: An integrative genomic analysis. Cancer Med. 2025 Jan;14(2):e70601.
2. Kobayashi R, Matsuda S, Nakamura K, Kawakubo H, Ho K, Morimoto Y, Hisaoka K, Hoshi Y, Takeuchi M, Fukuda K, Okui J, Nishihara H, Kitagawa Y. Clinical value of preoperative circulating tumor DNA before surgery in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol. 2025 Jan 21;51(5):109625.
3. Suzuki S, Akahane T, Tanimoto A, Higashi M, Kitazono I, Kirishima M, Nishigaki M, Ikeda T, Kanemitsu S, Nakazawa J, Akahane E, Nishihara H, Uozumi K, Yoshimitsu M, Ishitsuka K, Ueno SI. Comparison of actionable alterations in cancers with kinase fusion, mutation, and copy number alteration. PLoS One. 2025 Jan 23;20(1):e0305025.
4. Chikaishi Y, Matsuoka H, Sugihara E, Takeda M, Sumitomo M, Yamada S, Inaguma G, Omura Y, Cheong Y, Kobayashi Y, Nakauchi M, Hiro J, Masumori K, Otsuka K, Nishihara H, Suda K, Saya H, Takimoto T. Mutation analysis of TMB-high colorectal cancer: Insights into molecular pathways and clinical implications. Cancer Sci. 2025 Jan 16. Online ahead of print.
5. Kato Y, Seishima R, Hattori K, Kato H, Ishida H, Shigeta K, Okabayashi K, Sugihara E, Takimoto T, Nakamura K, Nishihara H, Saya H, Kitagawa Y. Significance of homologous recombinant deficiency as a biomarker for drug sensitivity in colorectal cancer. Br J Cancer. 2025 Feb 11. Online ahead of print.
6. Nagase Y, Kodama M, Aimono E, Nakamura K, Takamatsu R, Abe K, Yoshimura T, Chiyoda T, Yamagami W, Nishihara H. CXCL9 and CXCL13 shape endometrial cancer immune-activated microenvironment via tertiary lymphoid structure formation. Cancer Sci. 2025 Feb 17. Online ahead of print.
7. Suzuki S, Akahane T, Tanimoto A, Higashi M, Kitazono I, Kirishima M, Nishigaki M, Ikeda T, Kanemitsu S, Nakazawa J, Akahane E, Nishihara H, Uozumi K, Yoshimitsu M, Ishitsuka K, Ueno SI. Comparison of actionable alterations in cancers with kinase fusion, mutation, and copy number alteration. PLoS One. 2025 Jan 23;20(1):e0305025.
8. So E, Hayashi H, Shimozaki K, Horie S, Kishimoto S, Chida A, Saito Y, Tsugaru K, Hirata K, Tanishima S, Nishihara H, Kanai T, Hamamoto Y. Clinical utility of comprehensive genomic profiling for advanced pancreatic cancer: insights from real-world data analysis. Int J Clin Oncol. 2025 Feb 17. Online ahead of print.

症例報告

1. Murata Y, Kosaka T, Nakamura K, Baba Y, Arai E, Yasumizu Y, Matsumoto K, Nishihara H, Oya M. A case of testicular dysgenesis syndrome with squamous cell carcinoma of the prostate harboring a CDK12 mutation. IJU Case Rep. 2025 Jan 2;8(2):125-128.
2. Ito K, Nakamura K, Kajihara T, Shinozaki Y, Imura J, Sakuma H. Coexistence of complete intestinal tract, prostatic tissue, prostatic urethra and bladder structure in ovarian mature cystic teratoma: a case report. Med Mol Morphol. 2025 Mar;58(1)91.